{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T05:39:14Z","timestamp":1788845954598,"version":"build-2803163510"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2020,9,17]],"date-time":"2020-09-17T00:00:00Z","timestamp":1600300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Matrix metalloproteinase 9 (MMP9) expression in the tumor microenvironment is implicated in multiple protumorigenic processes. Andecaliximab (GS-5745), a monoclonal antibody targeting MMP9 with high affinity and selectivity, was evaluated in combination with gemcitabine and nab-paclitaxel in patients with advanced pancreatic adenocarcinoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>This phase I study was completed in two parts: part A was a dose-finding, monotherapy phase that enrolled patients with advanced solid tumors, and part B examined andecaliximab in combination with chemotherapy in specific patient cohorts. In the cohort of patients with pancreatic adenocarcinoma (n =\u200936), andecaliximab 800 mg every 2\u2009weeks was administered in combination with gemcitabine and nab-paclitaxel. Patients were treated until unacceptable toxicity, withdrawal of consent, disease progression, or death. Efficacy, safety, and biomarker assessments were performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Andecaliximab combined with gemcitabine and nab-paclitaxel appeared to be well tolerated and did not demonstrate any unusual toxicities in patients with pancreatic adenocarcinoma. The most common treatment-emergent adverse events were fatigue (75.0%), alopecia (55.6%), peripheral edema (55.6%), and nausea (50.0%). Median progression-free survival was 7.8 months (90% confidence interval, 6.9\u221211.0) with an objective response rate of 44.4% and median duration of response of 7.6 months. Maximal andecaliximab target binding, defined as undetectable, andecaliximab-free MMP9 in plasma, was observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Andecaliximab in combination with gemcitabine and nab-paclitaxel demonstrates a favorable safety profile and clinical activity in patients with advanced pancreatic adenocarcinoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Implications for Practice<\/jats:title>\n                    <jats:p>The combination of andecaliximab, a novel, first-in-class inhibitor of matrix metalloproteinase 9, with gemcitabine and nab-paclitaxel in patients with advanced pancreatic adenocarcinoma provided a median progression-free survival of 7.8 months and objective response rate of 44.4%. The majority of systemic biomarkers related to matrix metalloproteinase 9 activity and immune suppression increased at 2 months, whereas biomarkers related to tumor burden decreased. Although this study demonstrates promising results with andecaliximab plus chemotherapy in patients with advanced pancreatic adenocarcinoma, andecaliximab was not associated with a survival benefit in a phase III study in patients with advanced gastric\/gastroesophageal junction carcinoma.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1634\/theoncologist.2020-0474","type":"journal-article","created":{"date-parts":[[2020,9,11]],"date-time":"2020-09-11T12:08:51Z","timestamp":1599826131000},"page":"954-962","source":"Crossref","is-referenced-by-count":25,"title":["Safety and Efficacy of Andecaliximab (GS-5745) Plus Gemcitabine and Nab-Paclitaxel in Patients with Advanced Pancreatic Adenocarcinoma: Results from a Phase I Study"],"prefix":"10.1093","volume":"25","author":[{"given":"Johanna","family":"Bendell","sequence":"first","affiliation":[{"name":"Sarah Cannon Research Institute\/Tennessee Oncology, Nashville, Tennessee, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil","family":"Sharma","sequence":"additional","affiliation":[{"name":"Translational Genomics Research Institute, Phoenix, Arizona, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish R.","family":"Patel","sequence":"additional","affiliation":[{"name":"Florida Cancer Specialists\/Sarah Cannon Research Institute, Sarasota, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin S.","family":"Windsor","sequence":"additional","affiliation":[{"name":"Alabama Oncology, Birmingham, Alabama, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zev A.","family":"Wainberg","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology Oncology, University of California Los Angeles School of Medicine, Santa Monica, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Gordon","sequence":"additional","affiliation":[{"name":"HonorHealth Research Institute, Scottsdale, Arizona, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Chaves","sequence":"additional","affiliation":[{"name":"Northwest Medical Specialties, PLLC, Tacoma, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan","family":"Berlin","sequence":"additional","affiliation":[{"name":"Vanderbilt University Medical Center, Nashville, Tennessee, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrie Baker","family":"Brachmann","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc, Foster City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Zavodovskaya","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc, Foster City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JieJane","family":"Liu","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc, Foster City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dung","family":"Thai","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc, Foster City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pankaj","family":"Bhargava","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc, Foster City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish A.","family":"Shah","sequence":"additional","affiliation":[{"name":"Weill Cornell Medicine, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saad A.","family":"Khan","sequence":"additional","affiliation":[{"name":"Stanford University Medical Center, Stanford, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Starodub","sequence":"additional","affiliation":[{"name":"Riverside Peninsula Cancer Institute, Riverside Cancer Care Center, Newport News, Virginia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,9,17]]},"reference":[{"key":"2021122511251988300_onco13483-bib-0001","first-page":"127","article-title":"Matrix metalloproteinases: Their biological functions and clinical implications","volume":"106","author":"Hijova","year":"2005","journal-title":"Bratisl Lek Listy"},{"key":"2021122511251988300_onco13483-bib-0002","doi-asserted-by":"crossref","first-page":"222","DOI":"10.3109\/10409238.2013.770819","article-title":"Biochemistry and molecular biology of gelatinase b or matrix metalloproteinase-9 (MMP-9): The next decade","volume":"48","author":"Vandooren","year":"2013","journal-title":"Crit Rev Biochem Mol Biol"},{"key":"2021122511251988300_onco13483-bib-0003","doi-asserted-by":"crossref","first-page":"240","DOI":"10.3390\/cancers6010240","article-title":"Gelatinase B\/MMP-9 in tumour pathogenesis and progression","volume":"6","author":"Farina","year":"2014","journal-title":"Cancers (Basel)"},{"key":"2021122511251988300_onco13483-bib-0004","first-page":"518","article-title":"Prognostic value of matrix metalloproteinase-9 in gastric cancer: A meta-analysis","volume":"61","author":"Chen","year":"2014","journal-title":"Hepatogastroenterology"},{"key":"2021122511251988300_onco13483-bib-0005","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s00268-011-1192-6","article-title":"Correlation of vascular endothelial growth factor expression with tumor recurrence and poor prognosis in patients with pn0 gastric cancer","volume":"36","author":"Liu","year":"2012","journal-title":"World J Surg"},{"key":"2021122511251988300_onco13483-bib-0006","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1002\/ar.21071","article-title":"Expression of matrix metalloproteinase-9 mRNA and vascular endothelial growth factor protein in gastric carcinoma and its relationship to its pathological features and prognosis","volume":"293","author":"Yang","year":"2010","journal-title":"Anat Rec (Hoboken)"},{"key":"2021122511251988300_onco13483-bib-0007","doi-asserted-by":"crossref","DOI":"10.1186\/s13000-015-0445-3","article-title":"The co-expression of MMP-9 and Tenascin-c is significantly associated with the progression and prognosis of pancreatic cancer","volume":"10","author":"Xu","year":"2015","journal-title":"Diagn Pathol"},{"key":"2021122511251988300_onco13483-bib-0008","doi-asserted-by":"crossref","first-page":"4683","DOI":"10.1200\/JCO.2004.08.054","article-title":"Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: Eastern Cooperative Oncology Group trial E2196","volume":"22","author":"Sparano","year":"2004","journal-title":"J Clin Oncol"},{"key":"2021122511251988300_onco13483-bib-0009","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1038\/sj.bjc.6600310","article-title":"Marimastat as maintenance therapy for patients with advanced gastric cancer: A randomised trial","volume":"86","author":"Bramhall","year":"2002","journal-title":"Br J Cancer"},{"key":"2021122511251988300_onco13483-bib-0010","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0127063","article-title":"Selective allosteric inhibition of MMP9 is efficacious in preclinical models of ulcerative colitis and colorectal cancer","volume":"10","author":"Marshall","year":"2015","journal-title":"PLoS One"},{"key":"2021122511251988300_onco13483-bib-0011","doi-asserted-by":"crossref","first-page":"6810","DOI":"10.1074\/jbc.M116.760579","article-title":"Biochemical characterization and structure determination of a potent, selective antibody inhibitor of human MMP9","volume":"292","author":"Appleby","year":"2017","journal-title":"J Biol Chem"},{"key":"2021122511251988300_onco13483-bib-0012","doi-asserted-by":"crossref","first-page":"314","DOI":"10.4161\/self.1.4.13904","article-title":"Immunogenicity of protein therapeutics: The key causes, consequences and challenges","volume":"1","author":"Baker","year":"2010","journal-title":"Self Nonself"},{"key":"2021122511251988300_onco13483-bib-0013","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2165\/0126839-200809060-00004","article-title":"New approaches to prediction of immune responses to therapeutic proteins during preclinical development","volume":"9","author":"Perry","year":"2008","journal-title":"Drugs R D"},{"key":"2021122511251988300_onco13483-bib-0014","first-page":"589","article-title":"Concentrations and activities of metalloproteinases 2 and 9 and their inhibitors (TIMPs) in chronic pancreatitis and pancreatic adenocarcinoma","volume":"63","author":"Lekstan","year":"2012","journal-title":"J Physiol Pharmacol"},{"key":"2021122511251988300_onco13483-bib-0015","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1158\/1078-0432.CCR-1157-03","article-title":"Comprehensive analysis of matrix metalloproteinase and tissue inhibitor expression in pancreatic cancer: Increased expression of matrix metalloproteinase-7 predicts poor survival","volume":"10","author":"Jones","year":"2004","journal-title":"Clin Cancer Res"},{"key":"2021122511251988300_onco13483-bib-0016","volume-title":"Cancer stat facts: Pancreatic cancer. National Cancer Institute Web site","author":"National Cancer Institute, Surveillance, Epidemiology, and End Results Program","year":"2020"},{"key":"2021122511251988300_onco13483-bib-0017","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-018-4610-4","article-title":"Trends in pancreatic adenocarcinoma incidence and mortality in the United States in the last four decades; a SEER-based study","volume":"18","author":"Saad","year":"2018","journal-title":"BMC Cancer"},{"key":"2021122511251988300_onco13483-bib-0018","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1158\/1078-0432.CCR-17-2469","article-title":"Andecaliximab\/GS-5745 alone and combined with mFOLFOX6 in advanced gastric and gastroesophageal junction adenocarcinoma: Results from a phase I study","volume":"24","author":"Shah","year":"2018","journal-title":"Clin Cancer Res"},{"key":"2021122511251988300_onco13483-bib-0019","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N Engl J Med"},{"key":"2021122511251988300_onco13483-bib-0020","author":"National Comprehensive Cancer Network","year":"2017"},{"key":"2021122511251988300_onco13483-bib-0021","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N Engl J Med"},{"issue":"3","key":"2021122511251988300_onco13483-bib-0022","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/j.ajpath.2010.11.058","article-title":"Overexpression of CXCL5 is associated with poor survival in patients with pancreatic cancer","volume":"178","author":"Li","year":"2011","journal-title":"Am J Pathol"},{"key":"2021122511251988300_onco13483-bib-0023","article-title":"Prognostic significance of CXCL5 expression in cancer patients: a meta-analysis","volume":"18","author":"Hu","year":"2018","journal-title":"Can Cell Int"},{"key":"2021122511251988300_onco13483-bib-0024","article-title":"Crucial biological functions of CCL7 in cancer","volume":"6","author":"Cai","year":"2018","journal-title":"PeerJ"},{"issue":"4","key":"2021122511251988300_onco13483-bib-0025","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/jso.24335","article-title":"Elevated serum concentration of monocyte chemotactic protein 4 (MCP-4) as a novel non-invasive prognostic and predictive biomarker for detection of metastasis in colorectal cancer","volume":"114","author":"Okugawa","year":"2016","journal-title":"J Surg Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1634%2Ftheoncologist.2020-0474","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2020-0474","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2020-0474","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/25\/11\/954\/41922022\/oncolo_25_11_954.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/25\/11\/954\/41922022\/oncolo_25_11_954.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T06:26:52Z","timestamp":1640413612000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/25\/11\/954\/6443290"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,17]]},"references-count":25,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2020,9,17]]},"published-print":{"date-parts":[[2020,11,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2020-0474","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,11,1]]},"published":{"date-parts":[[2020,9,17]]}}}